Olon Group, a global pharmaceutical CDMO, appointed Jérôme Bédier as CEO of its French entities and Andrea Conforto as M&S VP CDMO of Olon Biotech, the division dedicated to CDMO services for biologics.

These appointments reinforce Olon’s strategy to expand its capabilities in Antibody-Drug Conjugates (ADCs), Highly Potent Active Pharmaceutical Ingredients (HPAPIs), and microbial bioproduction.

As CEO of Olon’s French entities, Jérôme Bédier will lead the integration of French CDMO capabilities within Olon Group and drive the expansion of Olon’s biopharmaceutical offering. He succeeds Alain Sainsot, who led GTP Bioways before its acquisition by Olon Group.

As M&S VP CDMO of Olon Biotech, Andrea Conforto will develop strategic partnerships with biotech companies and pharmaceutical firms across Europe, North America, and Asia.

With this new leadership structure, Olon Group is accelerating the development of its fully integrated ADC offering, covering the entire value chain from Cell Line Development (CLD) to drug product manufacturing, including payload and linker production. 

Olon Group is also leveraging its recent investments in its Rodano (Italy) site, which enhances its HPAPI production capabilities and aligns with its broader commitment to complex biopharmaceutical manufacturing.

Maurizio Sartorato, VP Biotech BU at Olon Group, commented: “Strengthening our leadership in bioproduction requires a global and integrated vision. With Jérôme and Andrea, we are reinforcing our expertise to address the growing needs of the ADC, HPAPI, and microbial bioproduction markets.”